Can a blood thinner protect Kids' hearts after kawasaki? small study aims to find out

NCT ID NCT06978439

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This pilot study tests the blood thinner Rivaroxaban in 10 Chinese children who developed giant coronary artery aneurysms after Kawasaki disease. The goal is to see if a specially adjusted dose can prevent new blood clots in the heart arteries while keeping bleeding risks low. Children will be followed for at least 6 months to track clots, major heart events, and any bleeding problems.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Rivaroxaban (Xarelto), a blood thinner
What this could lead to
If successful, this could point toward a safe and effective dosing strategy for Rivaroxaban to prevent dangerous blood clots in children with giant coronary artery aneurysms after Kawasaki disease.
What could go wrong
This is a very small pilot study with only 10 children, so results may not apply to all patients. The main risk is bleeding, which can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY ANEURYSM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Children's Hospital of Fudan University

    RECRUITING

    Shanghai, Shanghai Municipality, 201102, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.